- Home
- ALAR vs ATHA Comparison
ALAR vs ATHA Comparison
Compare ALAR & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- ATHA
- Stock Information
- Founded
- ALAR 2013
- ATHA 2011
- Country
- ALAR Israel
- ATHA United States
- Employees
- ALAR N/A
- ATHA N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- ALAR Technology
- ATHA Health Care
- Exchange
- ALAR Nasdaq
- ATHA Nasdaq
- Market Cap
- ALAR 94.0M
- ATHA 93.5M
- IPO Year
- ALAR 2018
- ATHA 2020
- Fundamental
- Price
- ALAR $13.20
- ATHA $0.66
- Analyst Decision
- ALAR Strong Buy
- ATHA Buy
- Analyst Count
- ALAR 2
- ATHA 4
- Target Price
- ALAR $25.50
- ATHA $11.25
- AVG Volume (30 Days)
- ALAR 245.7K
- ATHA 14.1M
- Earning Date
- ALAR 11-25-2024
- ATHA 11-07-2024
- Dividend Yield
- ALAR N/A
- ATHA N/A
- EPS Growth
- ALAR N/A
- ATHA N/A
- EPS
- ALAR 0.07
- ATHA N/A
- Revenue
- ALAR $31,117,000.00
- ATHA N/A
- Revenue This Year
- ALAR $22.15
- ATHA N/A
- Revenue Next Year
- ALAR $11.59
- ATHA N/A
- P/E Ratio
- ALAR $21.41
- ATHA N/A
- Revenue Growth
- ALAR 52.26
- ATHA N/A
- 52 Week Low
- ALAR $4.20
- ATHA $0.41
- 52 Week High
- ALAR $46.69
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- ALAR 43.35
- ATHA 51.13
- Support Level
- ALAR $12.05
- ATHA $0.62
- Resistance Level
- ALAR $16.07
- ATHA $0.69
- Average True Range (ATR)
- ALAR 1.24
- ATHA 0.09
- MACD
- ALAR -0.25
- ATHA 0.01
- Stochastic Oscillator
- ALAR 13.81
- ATHA 36.05
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.